论文信息 - Evaluation of nanomedicines: stick to the basics - 字舞流文

Evaluation of nanomedicines: stick to the basics

Scott E. McNeil | S. McNeil

[1] S. Groshen,et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[2] N. Sadrieh,et al. Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review. , 2011, Methods in molecular biology.

[3] W. Stigelman,et al. Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .

[4] J. Cortes,et al. Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. , 2016 .

[5] A. J. Tavares,et al. Analysis of nanoparticle delivery to tumours , 2016 .

[6] D. Tzemach,et al. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals , 1997 .

[7] Theresa M. Allen,et al. Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors , 2005, Clinical Cancer Research.

[8] S. Jeffers,et al. Pegylated liposomal doxorubicin ( doxil ) : Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg / m 2 , 2005 .